This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005307/en/
PROPEL Contour® (Photo: Business Wire)
Intersect ENT’s PROPEL Contour is a drug-eluting, bioabsorbable sinus implant that is placed in the frontal sinus (between the eyebrows) following sinus surgery. PROPEL Contour incorporates a unique hourglass design that conforms to the sinus openings that delivers an advanced corticosteroid with anti-inflammatory properties and mechanical support to help improve surgical outcomes. PROPEL Contour is clinically proven to reduce the need for additional interventions (surgical treatments and/or oral steroids) after sinus surgery by 65 percent.1 PROPEL Contour is the third localized drug delivery implant (inclusive of PROPEL and PROPEL Mini), completing the PROPEL family of drug-eluting, bioabsorbable implants now available to ENT specialists in select EU countries.
“After treating my first two patients with PROPEL Contour post-functional endoscopic sinus surgery in
About Intersect ENT®
For additional information on the Company or the products including risks and benefits, please visit www.IntersectENT.com. For more information about PROPEL® and SINUVA®, please visit www.IntersectENT.de and www.SINUVA.com
Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of
Important Safety Information for the PROPEL Sinus Implant
The PROPEL Contour sinus implant is intended for use in patients ≥ 18 years of age with chronic rhinosinusitis following sinus surgery to maintain patency of the frontal sinus ostia and to locally deliver mometasone furoate to the sinus mucosa. The PROPEL Contour sinus implant separates/dilates mucosal tissues, prevents obstruction by adhesions/scarring, and reduces edema. The implant reduces the need for post-operative intervention such as surgical adhesion lysis and/or use of oral steroids. For more information on the risks and benefits of PROPEL sinus implants, please visit www.intersectENT.com/products. For use by healthcare professionals only.
This release contains forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We may, in some cases, use terms such as “look forward,” confident,” “promises,” “predicts,” “believe,” “potential,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Intersect ENT’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation those related to the safety, efficacy and patient and physician adoption of the Company’s products and therapies, the ability to obtain and maintain reimbursement codes for its products, the Company’s ability to procure and maintain required regulatory approvals for our products, the Company’s ability to grow and expand its business, as well as other risks detailed from time to time in Intersect ENT’s filings with the
1. Data on File at
Executive Vice-President & CFO
Source: Intersect ENT®, Inc.